Document Detail


Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
MedLine Citation:
PMID:  20183436     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Phase II clinical trials are conducted to test whether a drug has a minimum desired effect and to assess whether further development of the drug is warranted. They are often designed as one-arm trials with response rate as the primary endpoint, and a two-stage design is often used to ensure early termination of the trial for futility. To control the type I error rate and guarantee the specified power of the study, planned sample sizes for both stages must be rigidly followed, but a literature review suggests that actual sample size often differs from that planned. We propose to extend simple two-stage designs to allow more flexible sampling plans in both stages. Our designs are preferable to similar extensions proposed to control type I and II error probabilities. Additionally, our assumptions regarding distribution of the actual sample size at the end of stage 1 are more lenient. A list of optimal designs for typical error rates and the selected null and alternative response rates is presented.
Authors:
Nobuyuki Masaki; Tatsuki Koyama; Isao Yoshimura; Chikuma Hamada
Related Documents :
18852316 - A method of extracting the number of trial participants from abstracts describing rando...
17650326 - Process evaluation for complex interventions in primary care: understanding trials usin...
22669656 - In vivo models of developmental toxicology.
7701146 - Internal pilot studies for estimating sample size.
22201416 - Comparative studies on some metrics for external validation of qspr models.
21522506 - Erratum: dichlorido{4-cyclo-hexyl-1-[1-(2-pyridyl-κn)ethyl-idene]thio-semicarbazidato-...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of biopharmaceutical statistics     Volume:  19     ISSN:  1520-5711     ISO Abbreviation:  J Biopharm Stat     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2010-02-25     Completed Date:  2010-05-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9200436     Medline TA:  J Biopharm Stat     Country:  England    
Other Details:
Languages:  eng     Pagination:  721-31     Citation Subset:  IM    
Affiliation:
Department of Biostatistics, Bristol-Myers K.K, Tokyo, Japan. nobuyuki.masaki@bms.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials, Phase II as Topic / statistics & numerical data*
Computer Simulation
Data Interpretation, Statistical
Humans
Models, Statistical*
Sample Size*
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A novel Gibbs maximum a posteriori (GMAP) approach on Bayesian nonlinear mixed-effects population ph...
Next Document:  Parametric modeling of localized melanoma prognosis and outcome.